Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021

J Transl Med. 2022 Jun 15;20(1):271. doi: 10.1186/s12967-022-03472-x.


After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a surrogate measure for long-term outcomes, therefore offering the ability for early and objective assessment of treatment efficacy and the potential to inform and personalize adjuvant treatment clinical decision-making. Leveraging the neoadjuvant treatment setting offers the ability to deeply interrogate longitudinal tissue in order to gain translatable, pan-malignancy insights into response and mechanisms of resistance to immunotherapy. Neoadjuvant immunotherapy across cancers was a focus of discussion at the virtual Immunotherapy Bridge meeting (December 1-2, 2021). Clinical, biomarker, and pathologic insights from prostate, breast, colon, and non-small-cell lung cancers, melanoma and non-melanoma skin cancers were discussed and are summarized in this report.

Keywords: CTLA-4; Checkpoint inhibitors; Immunotherapy; Neoadjuvant; PD-1; Pathological response.

Publication types

  • Congress

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Humans
  • Immunotherapy
  • Lung Neoplasms* / pathology
  • Male
  • Melanoma* / pathology
  • Neoadjuvant Therapy